Dale JD - Emmaus Life G Counsel

EMMADelisted Stock  USD 0.26  0.00  0.00%   

Insider

Dale JD is G Counsel of Emmaus Life Sciences
Phone310 214 0065
Webhttps://www.emmausmedical.com

Emmaus Life Management Efficiency

The company has return on total asset (ROA) of (0.1239) % which means that it has lost $0.1239 on every $100 spent on assets. This is way below average. Emmaus Life's management efficiency ratios could be used to measure how well Emmaus Life manages its routine affairs as well as how well it operates its assets and liabilities.
Emmaus Life Sciences currently holds 4.65 M in liabilities. Emmaus Life Sciences has a current ratio of 0.14, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Emmaus Life until it has trouble settling it off, either with new capital or with free cash flow. So, Emmaus Life's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Emmaus Life Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Emmaus to invest in growth at high rates of return. When we think about Emmaus Life's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Fangyong DuAdagene
54
Crystal MercadoAcrivon Therapeutics, Common
N/A
Rex CFAAnebulo Pharmaceuticals
64
Suzanne MessereNRx Pharmaceuticals
N/A
Scott AndersonAnebulo Pharmaceuticals
N/A
Seth VoorheesNRx Pharmaceuticals
63
Molly CoganNRx Pharmaceuticals
N/A
Peter MDAcrivon Therapeutics, Common
62
Jesper OlsenAcrivon Therapeutics, Common
N/A
Eric DevroeAcrivon Therapeutics, Common
46
Kenneth CundyAnebulo Pharmaceuticals
66
Erick MDAcrivon Therapeutics, Common
67
Man MBAAdagene
48
Jc MDAdagene
60
Michael KunzNRx Pharmaceuticals
59
Robert MIMNRx Pharmaceuticals
58
Rasmus HolmJorgensenAcrivon Therapeutics, Common
53
Philip LavinNRx Pharmaceuticals
78
Kristina MassonAcrivon Therapeutics, Common
44
Guizhong LiuAdagene
54
Daniel FagaAnaptysBio
45
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California. Emmaus Life operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 58 people. Emmaus Life Sciences [EMMA] is traded as part of a regulated electronic over-the-counter service offered by the NASD. Emmaus Life is listed under Healthcare category by Fama And French industry classification.

Management Performance

Emmaus Life Sciences Leadership Team

Elected by the shareholders, the Emmaus Life's board of directors comprises two types of representatives: Emmaus Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Emmaus. The board's role is to monitor Emmaus Life's management team and ensure that shareholders' interests are well served. Emmaus Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Emmaus Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
CPA CPA, Chief Officer
MS MBA, Consultant
Steven Lee, Independent Consultant
Dale JD, G Counsel
George Sekulich, VP Officer
PharmD PharmD, Clinical, Affairs
MD MPH, Chairman CEO
Willis MS, Vice COO

Emmaus Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Emmaus Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in population.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Other Consideration for investing in Emmaus OTC Stock

If you are still planning to invest in Emmaus Life Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Emmaus Life's history and understand the potential risks before investing.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years